Longevica takes in $2.5M as it launches open research resources to examine life extension

DMCA / Correction Notice
- Advertisement -

Life Science Company longevica On Wednesday it said it is launching an open research tool so that scientists and research institutions can access a data set that tracks the effects of more than 1,000 medicinal compounds to test drugs.

- Advertisement -

This is the latest effort from the biotechnology company, which is researching mechanisms of healthy aging and life extension. To do this, the company raised $2.5 million in funding led by Exploration Capital.

In April, Longevica announced the launch of a range of dietary supplements based on its research. The company started 11 years ago and has now raised more than $15.5 million in funding from investors, including a longtime investor, Alexander Chikunov, who is also the company’s chairman.


When the company emerged from stealth, it was primarily focused on finding the best ways to quickly leverage the results of its research and bring certain consumer-ready products to market, said Longevica co-founder and CEO Einar Abdrakhmanov. told Nerdshala via email.

“We still go down this path, which includes screening and testing; However, through a series of in-depth interviews, we found that most scientists in the longevity space lack the infrastructure, and we sought to take advantage of more research through partnerships and by giving researchers a data platform for their work. We have decided to share our internal engine.”

- Advertisement -

Living longer is an area in which other companies are also working for both humans and pets. NS Global Anti-aging Drugs Market It was valued at around $8 billion in 2020 and is projected to double by 2027.

Meanwhile, CrunchBase News took a look at Longevity startup status In July and more than 30 active ones were found in space that collectively raised billions of dollars. A more recent example is Loyal, which raised $27 million to investigate longer lifespans in animals with a long-term vision of translating that into human longevity.

Longevica itself started fundraising when it came up with the idea for an end-to-end open research platform. The new funding will go towards supporting the development of the platform and the integration of the company’s research data sets.

The goal is to validate the pipeline of turning scientific research into consumer-ready products, Abdrakhmanov said.

“There are a lot of hypotheses about aging and lifespan, but there’s a clear bottleneck in actually testing those ideas to see which might be right,” he said. “Our platform should help bring the scientific community closer to the answers.”

Its original study, led by Chikunov and Longevica co-founder Dr. Alexey Ryazanov, tested 300 compounds and showed significant life-extension properties. The company is close to publishing a peer-reviewed paper on that study. Abdrakhmanov called it “more of a moonlight project,” but also that the direction could bring results much sooner and be beneficial to the entire industry, which its investors could see, he said.

With new research capabilities, Longevica will now go deeper into testing those compounds with a new research study at the Jackson Laboratory. In January, the company will begin collecting applications from researchers interested in testing its drugs in a full-scale pharmacological screening experiment beginning in June 2022.

“Also in January, we will launch a public database, which includes marked data on the most longevity-related experiments on rats, both public and some that have not yet been published,” Abdrakhmanov said. “The entire platform will be free and open source, with even its program code publicly available on GitHub.”

- Advertisement -

Stay on top - Get the daily news in your inbox

Recent Articles

Related Stories